2. Academic Validation
  3. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships

Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships

  • Bioorg Med Chem Lett. 2012 Oct 15;22(20):6338-42. doi: 10.1016/j.bmcl.2012.08.086.
Masaki Miyazaki 1,  Haruko Kawato,  Hiroyuki Naito,  Masahiro Ikeda,  Masaya Miyazaki,  Mayumi Kitagawa,  Takahiko Seki,  Setsuko Fukutake,  Masashi Aonuma,  Tsunehiko Soga
Affiliations

Affiliation

  • 1 Lead Discovery & Optimization Research Laboratories II, R&D Division, Daiichi Sankyo Co., Ltd, Tokyo, Japan. miyazaki.masaki.p3@daiichisankyo.co.jp
PMID: 22995624 DOI: 10.1016/j.bmcl.2012.08.086
Abstract

Starting with Nutlins as an initial lead, we designed and generated bicyclic scaffolds aiming to place cis-bischlorophenyl moiety at the equivalent location where the hydrophobic interaction with MDM2 could be expected. As a result, we discovered novel MDM2 inhibitors possessing a dihydroimidazothiazole scaffold. Further exploration of the side chains on the dihydroimidazothiazole scaffold aided by molecular modeling resulted in compounds exhibiting almost comparable in vitro potency to Nutlin-3a.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z